Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") today announced that Ono submitted ...

More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline. DCC-3084, a pan-RAF inhibitor, “is no longer in our pipeline and we ...

On a bad day for the stock market overall, Deciphera Pharmaceuticals (NASDAQ: DCPH) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch of a ...

Last May, Deciphera Pharmaceuticals’ Qinlock became the first drug the FDA specifically approved for heavily pretreated patients with gastrointestinal stromal tumor. But now, a trial flop has squashed ...

Join the “New Developments in PCNSL Treatment” webinar to learn about new research, clinical trials, specialists, ...

OSAKA, Japan & WALTHAM, Mass., November 17, 2025--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

Lawrence-based Deciphera Pharmaceuticals LLC is teaming up with Eli Lilly and Co. to license and develop technology designed to fight cancer, in a partnership announced Friday that ultimately could ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection ...